Invasive mucinous adenocarcinoma misdiagnosed as pneumonia: A case report

Yang,Yuping; Huang,Rongfei; Xiang,Liping; Zeng,Jun; Zhao,Wei; Huang,Na

doi:10.3892/etm.2023.11867

Invasive mucinous adenocarcinoma misdiagnosed as pneumonia: A case report

Authors:
- Yuping Yang
- Rongfei Huang
- Liping Xiang
- Jun Zeng
- Wei Zhao
- Na Huang
View Affiliations

Affiliations: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China, Department of Pathology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China, School of Laboratory Medicine, Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China
Published online on: February 28, 2023 https://doi.org/10.3892/etm.2023.11867
Article Number: 168
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Common imaging findings of invasive mucinous adenocarcinoma (IMA) include consolidation of the lung parenchyma, nodules, and ground‑glass changes. However, the IMA imaging findings in the present case included diffuse, patchy and blurry density shadows through both lungs. To the best of the authors' knowledge, this image pattern has rarely been reported. The patient provided his consent and authorized the publication of photographs featuring his likeness. The present study reported a patient was diagnosed with IMA via pathologic and genetic analyses. Following antibiotic treatment, the lesions in both sides became larger. Further examinations were completed and IMA was confirmed by biopsy pathohistological examination. Pathological specimens were negative for almost all driver genes mutations, except KRAS. The patients and family refused further treatment, including chemotherapy, radiotherapy and interventional chemotherapy and the patient was discharged from The First Affiliated Hospital of Chengdu Medical College. The present case report emphasized that IMA should be suspected when imaging studies show diffuse lesions throughout both lungs. When a patient does not respond to treatment, clinicians should consider alternative diagnoses.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Sheng A, Zhou P, Ye Y, Sun K and Yang Z: Diagnostic efficacy of CT radiomic features in pulmonary invasive mucinous adenocarcinoma. Scanning. 2022(5314225)2022.PubMed/NCBI View Article : Google Scholar
3	Xu X, Shen W, Wang D, Li N, Huang Z, Sheng J, Rucker AJ, Mao W, Xu H and Cheng G: . Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma. Transl Lung Cancer Res. 11:420–431. 2022.PubMed/NCBI View Article : Google Scholar
4	Butt YM and Allen TC: The demise of the term bronchioloalveolar carcinoma. Arch Pathol Lab Med. 139:981–983. 2015.PubMed/NCBI View Article : Google Scholar
5	Read WL, Page NC, Tierney RM, Piccirillo JF and Govindan R: The epidemiology of bronchioloalveolar carcinoma over the past two decades: Analysis of the SEER database. Lung Cancer. 45:137–142. 2004.PubMed/NCBI View Article : Google Scholar
6	Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, et al: The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma. J Cancer Res Ther. 16:737–744. 2020.PubMed/NCBI View Article : Google Scholar
7	Gardiner N, Jogai S and Wallis A: The revised lung adenocarcinoma classification-an imaging guide. J Thorac Dis. 6:537–546. 2014.PubMed/NCBI View Article : Google Scholar
8	Moser L, Kegler K, Precht C and Zanolari P: Bronchioalveolar carcinoma in an adult alpaca (Vicugna pacos). BMC Vet Res. 15(139)2019.PubMed/NCBI View Article : Google Scholar
9	He Y, Huang H, Xu M, Fu Z, Zhang X, Chen X and Guo W: The effect of afatinib in a pretreated patient with invasive mucinous adenocarcinoma of the lung harboring HER2 YVMA insertion: A case report. Transl Cancer Res. 11:1819–1823. 2022.PubMed/NCBI View Article : Google Scholar
10	Chi K, Sun W, Yang X, Wu J, Wang H, Liu X, Mao L, Zhou L, Huang X and Lin D: A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS-mutant invasive non-mucinous adenocarcinoma. Thorac Cancer. 13:1050–1058. 2022.PubMed/NCBI View Article : Google Scholar
11	Kimura S, Onishi I and Kobayashi M: A rare case of esophageal metastasis of invasive mucinous adenocarcinoma of the lung. ACG Case Rep J. 9(e00857)2022.PubMed/NCBI View Article : Google Scholar
12	Chen X, Zhao Y, Wang D, Lin Y, Hou J, Xu X, Wu J, Zhong L, Zhou Y, Shen J, et al: The HNF4α-BC200-FMR1-positive feedback loop promotes growth and metastasis in invasive mucinous lung adenocarcinoma. Cancer Res. 81:5904–5918. 2021.PubMed/NCBI View Article : Google Scholar
13	Zhang X, Qiao W, Kang Z, Pan C, Chen Y, Li K, Shen W and Zhang L: CT features of stage IA invasive mucinous adenocarcinoma of the lung and establishment of a prediction model. Int J Gen Med. 15:5455–5463. 2022.PubMed/NCBI View Article : Google Scholar
14	Zhu D, Zhang Q, Rui Z and Xu S: Pulmonary invasive mucinous adenocarcinoma mimicking pulmonary actinomycosis. BMC Pulm Med. 22(181)2022.PubMed/NCBI View Article : Google Scholar
15	Mir E, Sareen R, Kulshreshtha R and Shah A: Bronchioloalveolar cell carcinoma presenting as a ‘non-resolving consolidation’ for two years. Pneumonol Alergol Pol. 83:208–211. 2015.PubMed/NCBI View Article : Google Scholar
16	Narahari NK, Uppin SG, Kapoor A, Stalin BJ and Paramjyothi GK: Invasive mucinous adenocarcinoma of the lung in a 19-year-old female. Asian Cardiovasc Thorac Ann. 26:635–639. 2018.PubMed/NCBI View Article : Google Scholar
17	Nie K, Nie W, Zhang YX and Yu H: Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings. Cancer Imaging. 19(47)2019.PubMed/NCBI View Article : Google Scholar
18	Kim DH, Bae SY, Na KJ, Park S, Park IK, Kang CH and Kim YT: Radiological and clinical features of screening-detected pulmonary invasive mucinous adenocarcinoma. Interact Cardiovasc Thorac Surg. 34:229–235. 2022.PubMed/NCBI View Article : Google Scholar
19	Wang T, Yang Y, Liu X, Deng J, Wu J, Hou L, Wu C, She Y, Sun X, Xie D and Chen C: Primary invasive mucinous adenocarcinoma of the lung: prognostic value of CT imaging features combined with clinical factors. Korean J Radiol. 22:652–662. 2021.PubMed/NCBI View Article : Google Scholar
20	Horiguchi T, Yanagi S, Tomita M, Maeda R, Uto K, Shigekusa T, Tsubouchi H, Matsumoto N and Nakazato M: A case of bilateral invasive mucinous adenocarcinoma of the lung with severe productive cough and dyspnea successfully treated with palliative lung lobectomy. Respir Med Case Rep. 32(101368)2021.PubMed/NCBI View Article : Google Scholar
21	Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, et al: Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: Invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 38:1118–1127. 2014.PubMed/NCBI View Article : Google Scholar
22	Boland JM, Maleszewski JJ, Wampfler JA, Voss JS, Kipp BR, Yang P and Yi ES: Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis. Hum Pathol. 71:8–19. 2018.PubMed/NCBI View Article : Google Scholar
23	Cha YJ, Kim HR, Lee HJ, Cho BC and Shim HS: Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer. 102:82–88. 2016.PubMed/NCBI View Article : Google Scholar
24	Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS and Iafrate AJ: Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 10:1156–1162. 2015.PubMed/NCBI View Article : Google Scholar
25	Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, Bi Y, Liu J, Rahman A, Wearne E, et al: FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 28:1482–1486. 2022.PubMed/NCBI View Article : Google Scholar
26	Frontline promise for Adagrasib-Pembrolizumab combination. Cancer Discov. 13(OF2)2022.PubMed/NCBI View Article : Google Scholar
27	Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et al: Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 30:1321–1328. 2019.PubMed/NCBI View Article : Google Scholar
28	Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, Otake S, Amemiya K, Oyama T, Mochizuki H and Omata M: Genomic characteristics of invasive mucinous adenocarcinomas of the lung and potential therapeutic targets of B7-H3. Cancers. 10:2018.PubMed/NCBI View Article : Google Scholar
29	Xu X, Li N, Wang D, Chen W and Fan Y: Clinical relevance of PD-L1 expression and CD8⁺ T cells' infiltration in patients with lung invasive mucinous adenocarcinoma. Front Oncol. 11(683432)2021.PubMed/NCBI View Article : Google Scholar